Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia

BACKGROUND: Expression of Bcr-Abl in hematopoietic stem cells is sufficient to cause chronic myeloid leukemia (CML) and tyrosine kinase inhibitors (TKI) induce molecular remission in the majority of CML patients. However, the disease driving stem cell population is not fully targeted by TKI therapy,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Autores principales: Herrmann, Oliver, Kuepper, Maja Kim, Bütow, Marlena, Costa, Ivan G., Appelmann, Iris, Beier, Fabian, Luedde, Tom, Braunschweig, Till, Koschmieder, Steffen, Brümmendorf, Tim H., Schemionek, Mirle
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6610865/
https://ncbi.nlm.nih.gov/pubmed/31272418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5871-2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares